<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;ff=20240423203844
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;ff=20240423203844" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 24 Apr 2024 00:38:46 +0000</lastbuilddate>
<pubDate>Mon, 22 Apr 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>No benefit of β-blockers after myocardial infarction with preserved ejection fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38649758/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Apr 22. doi: 10.1038/s41569-024-01030-0. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38649758/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38649758</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01030-0>10.1038/s41569-024-01030-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38649758</guid>
<pubDate>Mon, 22 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2024-04-22</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>No benefit of β-blockers after myocardial infarction with preserved ejection fraction</dc:title>
<dc:identifier>pmid:38649758</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01030-0</dc:identifier>
</item>
<item>
<title>Mediating Metabolism: Inhibition of Malic Enzyme 1 (ME1) Restores Endothelial Bioenergetics and Adenosine Signaling in Pulmonary Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38648276/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 23;149(17):1372-1374. doi: 10.1161/CIRCULATIONAHA.124.068738. Epub 2024 Apr 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38648276/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38648276</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068738>10.1161/CIRCULATIONAHA.124.068738</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38648276</guid>
<pubDate>Mon, 22 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Rashmi J Rao</dc:creator>
<dc:creator>Stephen Y Chan</dc:creator>
<dc:date>2024-04-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Mediating Metabolism: Inhibition of Malic Enzyme 1 (ME1) Restores Endothelial Bioenergetics and Adenosine Signaling in Pulmonary Hypertension</dc:title>
<dc:identifier>pmid:38648276</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068738</dc:identifier>
</item>
<item>
<title>Much Ado About Nothing? CABG or PCI for Left Main Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38648275/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 23;149(17):1339-1340. doi: 10.1161/CIRCULATIONAHA.124.069354. Epub 2024 Apr 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38648275/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38648275</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069354>10.1161/CIRCULATIONAHA.124.069354</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38648275</guid>
<pubDate>Mon, 22 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Jay Giri</dc:creator>
<dc:creator>Tsuyoshi Kaneko</dc:creator>
<dc:date>2024-04-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Much Ado About Nothing? CABG or PCI for Left Main Coronary Artery Disease</dc:title>
<dc:identifier>pmid:38648275</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069354</dc:identifier>
</item>
<item>
<title>Sifting for Gold in Terabytes of Data: Illuminating Cardiovascular Biology in the 'Omics Age</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38648274/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 23;149(17):1323-1325. doi: 10.1161/CIRCULATIONAHA.123.066988. Epub 2024 Apr 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38648274/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38648274</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066988>10.1161/CIRCULATIONAHA.123.066988</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38648274</guid>
<pubDate>Mon, 22 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Svati H Shah</dc:creator>
<dc:creator>Robert E Gerszten</dc:creator>
<dc:date>2024-04-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Sifting for Gold in Terabytes of Data: Illuminating Cardiovascular Biology in the 'Omics Age</dc:title>
<dc:identifier>pmid:38648274</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066988</dc:identifier>
</item>
<item>
<title>Trends in Age, Sex, and Racial Differences in the Incidence of Infective Endocarditis in Florida and New York</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38648273/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 23;149(17):1391-1393. doi: 10.1161/CIRCULATIONAHA.123.066921. Epub 2024 Apr 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38648273/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38648273</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066921>10.1161/CIRCULATIONAHA.123.066921</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38648273</guid>
<pubDate>Mon, 22 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Anderson Anuforo</dc:creator>
<dc:creator>Ehimen Aneni</dc:creator>
<dc:creator>Emmanuel Akintoye</dc:creator>
<dc:creator>Nnabuchi Anikpezie</dc:creator>
<dc:creator>Smit D Patel</dc:creator>
<dc:creator>Ayorinde Soipe</dc:creator>
<dc:creator>Eloho Olojakpoke</dc:creator>
<dc:creator>Devin Burke</dc:creator>
<dc:creator>Julius Gene Latorre</dc:creator>
<dc:creator>Priyank Khandelwal</dc:creator>
<dc:creator>Seemant Chaturvedi</dc:creator>
<dc:creator>Bruce Ovbiagele</dc:creator>
<dc:creator>Fadar Oliver Otite</dc:creator>
<dc:date>2024-04-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Trends in Age, Sex, and Racial Differences in the Incidence of Infective Endocarditis in Florida and New York</dc:title>
<dc:identifier>pmid:38648273</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066921</dc:identifier>
</item>
<item>
<title>Autonomic Dysfunction Linked to Inhibition of the Na&lt;sub>;v&lt;/sub>;1.7 Sodium Channel</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38648272/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 23;149(17):1394-1396. doi: 10.1161/CIRCULATIONAHA.123.067331. Epub 2024 Apr 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38648272/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38648272</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067331>10.1161/CIRCULATIONAHA.123.067331</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38648272</guid>
<pubDate>Mon, 22 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Christopher P Regan</dc:creator>
<dc:creator>Pierre Morissette</dc:creator>
<dc:creator>Richard L Kraus</dc:creator>
<dc:creator>Erjia Wang</dc:creator>
<dc:creator>Leticia Arrington</dc:creator>
<dc:creator>Marissa Vavrek</dc:creator>
<dc:creator>Jan de Hoon</dc:creator>
<dc:creator>Marleen Depre</dc:creator>
<dc:creator>Thomas Lodeweyck</dc:creator>
<dc:creator>Ignace Demeyer</dc:creator>
<dc:creator>Tine Laethem</dc:creator>
<dc:creator>Aubrey Stoch</dc:creator>
<dc:creator>Arie Struyk</dc:creator>
<dc:date>2024-04-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Autonomic Dysfunction Linked to Inhibition of the Na&lt;sub>;v&lt;/sub>;1.7 Sodium Channel</dc:title>
<dc:identifier>pmid:38648272</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067331</dc:identifier>
</item>
<item>
<title>Making House Calls</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38648271/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 23;149(17):1326-1327. doi: 10.1161/CIRCULATIONAHA.123.068553. Epub 2024 Apr 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38648271/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38648271</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068553>10.1161/CIRCULATIONAHA.123.068553</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38648271</guid>
<pubDate>Mon, 22 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Laurence Sperling</dc:creator>
<dc:date>2024-04-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Making House Calls</dc:title>
<dc:identifier>pmid:38648271</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068553</dc:identifier>
</item>
<item>
<title>New light shed on Anderson-Fabry, peripartum, and early-onset cardiomyopathies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38643479/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 21;45(16):1379-1383. doi: 10.1093/eurheartj/ehae226.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38643479/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38643479</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae226>10.1093/eurheartj/ehae226</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38643479</guid>
<pubDate>Sun, 21 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-04-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>New light shed on Anderson-Fabry, peripartum, and early-onset cardiomyopathies</dc:title>
<dc:identifier>pmid:38643479</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae226</dc:identifier>
</item>
<item>
<title>Self-expanding valves more beneficial than balloon-expandable valves in patients with a small aortic annulus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38641756/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Apr 19. doi: 10.1038/s41569-024-01027-9. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38641756/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38641756</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01027-9>10.1038/s41569-024-01027-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38641756</guid>
<pubDate>Fri, 19 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2024-04-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Self-expanding valves more beneficial than balloon-expandable valves in patients with a small aortic annulus</dc:title>
<dc:identifier>pmid:38641756</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01027-9</dc:identifier>
</item>
<item>
<title>Retraction of: Abstract 13079: Prevalence and Incidence of Transthyretin Amyloid Cardiomyopathy in the USA From 2004 to 2022: An Observational Database Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38639556/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):e1027. doi: 10.1161/CIR.0000000000001239. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38639556/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38639556</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001239>10.1161/CIR.0000000000001239</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38639556</guid>
<pubDate>Fri, 19 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Retraction of: Abstract 13079: Prevalence and Incidence of Transthyretin Amyloid Cardiomyopathy in the USA From 2004 to 2022: An Observational Database Study</dc:title>
<dc:identifier>pmid:38639556</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001239</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 18539</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38639555/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):e1025. doi: 10.1161/CIR.0000000000001237. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38639555/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38639555</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001237>10.1161/CIR.0000000000001237</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38639555</guid>
<pubDate>Fri, 19 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 18539</dc:title>
<dc:identifier>pmid:38639555</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001237</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 15684</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38639554/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):e1024. doi: 10.1161/CIR.0000000000001238. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38639554/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38639554</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001238>10.1161/CIR.0000000000001238</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38639554</guid>
<pubDate>Fri, 19 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 15684</dc:title>
<dc:identifier>pmid:38639554</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001238</dc:identifier>
</item>
<item>
<title>GLI1+ Cells Contribute to Vascular Remodeling in Pulmonary Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38639105/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our data highlight GLI1+ cells as an alternative cellular source of VSMCs in pulmonary hypertension and suggest that these cells and the associated signaling pathways represent an important therapeutic target for further studies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 19. doi: 10.1161/CIRCRESAHA.123.323736. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The precise origin of newly formed ACTA2+ (alpha smooth muscle actin-positive) cells appearing in nonmuscularized vessels in the context of pulmonary hypertension is still debatable although it is believed that they predominantly derive from preexisting vascular smooth muscle cells (VSMCs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: <i>Gli1</i><sup><i>Cre-ERT2</i></sup><i>; tdTomato</i><sup><i>flox</i></sup> mice were used to lineage trace GLI1+ (glioma-associated oncogene homolog 1-positive) cells in the context of pulmonary hypertension using 2 independent models of vascular remodeling and reverse remodeling: hypoxia and cigarette smoke exposure. Hemodynamic measurements, right ventricular hypertrophy assessment, flow cytometry, and histological analysis of thick lung sections followed by state-of-the-art 3-dimensional reconstruction and quantification using Imaris software were used to investigate the contribution of GLI1+ cells to neomuscularization of the pulmonary vasculature.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The data show that GLI1+ cells are abundant around distal, nonmuscularized vessels during steady state, and this lineage contributes to around 50% of newly formed ACTA2+ cells around these normally nonmuscularized vessels. During reverse remodeling, cells derived from the GLI1+ lineage are largely cleared in parallel to the reversal of muscularization. Partial ablation of GLI1+ cells greatly prevented vascular remodeling in response to hypoxia and attenuated the increase in right ventricular systolic pressure and right heart hypertrophy. Single-cell RNA sequencing on sorted lineage-labeled GLI1+ cells revealed an <i>Acta2</i><sup><i>high</i></sup> fraction of cells with pathways in cancer and MAPK signaling as potential players in reprogramming these cells during vascular remodeling. Analysis of human lung-derived material suggests that GLI1 signaling is overactivated in both group 1 and group 3 pulmonary hypertension and can promote proliferation and myogenic differentiation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our data highlight GLI1+ cells as an alternative cellular source of VSMCs in pulmonary hypertension and suggest that these cells and the associated signaling pathways represent an important therapeutic target for further studies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38639105/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38639105</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323736>10.1161/CIRCRESAHA.123.323736</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38639105</guid>
<pubDate>Fri, 19 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Xuran Chu</dc:creator>
<dc:creator>Vahid Kheirollahi</dc:creator>
<dc:creator>Arun Lingampally</dc:creator>
<dc:creator>Prakash Chelladurai</dc:creator>
<dc:creator>Chanil Valasarajan</dc:creator>
<dc:creator>Ana Ivonne Vazquez-Armendariz</dc:creator>
<dc:creator>Stefan Hadzic</dc:creator>
<dc:creator>Ali Khadim</dc:creator>
<dc:creator>Oleg Pak</dc:creator>
<dc:creator>Stefano Rivetti</dc:creator>
<dc:creator>Jochen Wilhelm</dc:creator>
<dc:creator>Marek Bartkuhn</dc:creator>
<dc:creator>Slaven Crnkovic</dc:creator>
<dc:creator>Alena Moiseenko</dc:creator>
<dc:creator>Monika Heiner</dc:creator>
<dc:creator>Simone Kraut</dc:creator>
<dc:creator>Leila Sotoodeh</dc:creator>
<dc:creator>Janine Koepke</dc:creator>
<dc:creator>Guilherme Valente</dc:creator>
<dc:creator>Clemens Ruppert</dc:creator>
<dc:creator>Thomas Braun</dc:creator>
<dc:creator>Christos Samakovlis</dc:creator>
<dc:creator>Ioannis Alexopoulos</dc:creator>
<dc:creator>Mario Looso</dc:creator>
<dc:creator>Cho-Ming Chao</dc:creator>
<dc:creator>Susanne Herold</dc:creator>
<dc:creator>Werner Seeger</dc:creator>
<dc:creator>Grazyna Kwapiszewska</dc:creator>
<dc:creator>Xiaoying Huang</dc:creator>
<dc:creator>Jin-San Zhang</dc:creator>
<dc:creator>Soni Savai Pullamsetti</dc:creator>
<dc:creator>Norbert Weissmann</dc:creator>
<dc:creator>Xiaokun Li</dc:creator>
<dc:creator>Elie El Agha</dc:creator>
<dc:creator>Saverio Bellusci</dc:creator>
<dc:date>2024-04-19</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>GLI1+ Cells Contribute to Vascular Remodeling in Pulmonary Hypertension</dc:title>
<dc:identifier>pmid:38639105</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323736</dc:identifier>
</item>
<item>
<title>Single-Cell Gene-Regulatory Networks of Advanced Symptomatic Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38639096/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: By identifying and integrating the most gene-rich single-cell subclusters of atherosclerosis to date with a coronary artery disease framework of GRNs, GRN39 was identified and independently validated as being critical for the transformation of contractile SMCs into an osteogenic phenotype promoting advanced-stage, symptomatic atherosclerosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 19. doi: 10.1161/CIRCRESAHA.123.323184. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: While our understanding of the single-cell gene expression patterns underlying the transformation of vascular cell types during the progression of atherosclerosis is rapidly improving, the clinical and pathophysiological relevance of these changes remains poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Single-cell RNA sequencing data generated with SmartSeq2 (≈8000 genes/cell) in nearly 19 000 single cells isolated during atherosclerosis progression in <i>Ldlr</i><sup><i>-/-</i></sup><i>Apob</i><sup><i>100/100</i></sup> mice with human-like plasma lipoproteins and from humans with asymptomatic and symptomatic carotid plaques was clustered into multiple subtypes. For clinical and pathophysiological context, the advanced-stage and symptomatic subtype clusters were integrated with 135 tissue-specific (atherosclerotic aortic wall, mammary artery, liver, skeletal muscle, and visceral and subcutaneous, fat) gene-regulatory networks (GRNs) inferred from 600 coronary artery disease patients in the STARNET (Stockholm-Tartu Atherosclerosis Reverse Network Engineering Task) study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Advanced stages of atherosclerosis progression and symptomatic carotid plaques were largely characterized by 3 smooth muscle cells (SMCs), and 3 macrophage subtype clusters with extracellular matrix organization/osteogenic (SMC), and M1-type proinflammatory/Trem2-high lipid-associated (macrophage) phenotypes. Integrative analysis of these 6 clusters with STARNET revealed significant enrichments of 3 arterial wall GRNs: GRN33 (macrophage), GRN39 (SMC), and GRN122 (macrophage) with major contributions to coronary artery disease heritability and strong associations with clinical scores of coronary atherosclerosis severity (SYNTAX/Duke scores). The presence and pathophysiological relevance of GRN39 were verified in 5 independent RNAseq data sets obtained from the human coronary and aortic artery, and primary SMCs and by targeting its top-key drivers, <i>FRZB</i> and <i>ALCAM</i>, in cultured human vascular SMCs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: By identifying and integrating the most gene-rich single-cell subclusters of atherosclerosis to date with a coronary artery disease framework of GRNs, GRN39 was identified and independently validated as being critical for the transformation of contractile SMCs into an osteogenic phenotype promoting advanced-stage, symptomatic atherosclerosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38639096/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38639096</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323184>10.1161/CIRCRESAHA.123.323184</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38639096</guid>
<pubDate>Fri, 19 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Giuseppe Mocci</dc:creator>
<dc:creator>Katyayani Sukhavasi</dc:creator>
<dc:creator>Tiit Örd</dc:creator>
<dc:creator>Sean Bankier</dc:creator>
<dc:creator>Prosanta Singha</dc:creator>
<dc:creator>Uma Thanigai Arasu</dc:creator>
<dc:creator>Olayinka Oluwasegun Agbabiaje</dc:creator>
<dc:creator>Petri Mäkinen</dc:creator>
<dc:creator>Lijiang Ma</dc:creator>
<dc:creator>Chani J Hodonsky</dc:creator>
<dc:creator>Redouane Aherrahrou</dc:creator>
<dc:creator>Lars Muhl</dc:creator>
<dc:creator>Jianping Liu</dc:creator>
<dc:creator>Sonja Gustafsson</dc:creator>
<dc:creator>Byambajav Byandelger</dc:creator>
<dc:creator>Ying Wang</dc:creator>
<dc:creator>Simon Koplev</dc:creator>
<dc:creator>Urban Lendahl</dc:creator>
<dc:creator>Gary Owens</dc:creator>
<dc:creator>Nicholas J Leeper</dc:creator>
<dc:creator>Gerard Pasterkamp</dc:creator>
<dc:creator>Michael Vanlandewijck</dc:creator>
<dc:creator>Tom Michoel</dc:creator>
<dc:creator>Arno Ruusalepp</dc:creator>
<dc:creator>Ke Hao</dc:creator>
<dc:creator>Seppo Ylä-Herttuala</dc:creator>
<dc:creator>Marika Väli</dc:creator>
<dc:creator>Heli Järve</dc:creator>
<dc:creator>Michal Mokry</dc:creator>
<dc:creator>Mete Civelek</dc:creator>
<dc:creator>Clint Miller</dc:creator>
<dc:creator>Jason C Kovacic</dc:creator>
<dc:creator>Minna U Kaikkonen</dc:creator>
<dc:creator>Christer Betsholtz</dc:creator>
<dc:creator>Johan L M Björkegren</dc:creator>
<dc:date>2024-04-19</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Single-Cell Gene-Regulatory Networks of Advanced Symptomatic Atherosclerosis</dc:title>
<dc:identifier>pmid:38639096</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323184</dc:identifier>
</item>
<item>
<title>Mitochondrial CypD Acetylation Promotes Endothelial Dysfunction and Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38639088/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These data support the pathogenic role of CypD acetylation in endothelial dysfunction and hypertension. We suggest that targeting cytotoxic mitochondrial isolevuglandins and GCN5L1 reduces CypD acetylation, which may be beneficial in cardiovascular disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 19. doi: 10.1161/CIRCRESAHA.123.323596. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Nearly half of adults have hypertension, a major risk factor for cardiovascular disease. Mitochondrial hyperacetylation is linked to hypertension, but the role of acetylation of specific proteins is not clear. We hypothesized that acetylation of mitochondrial CypD (cyclophilin D) at K166 contributes to endothelial dysfunction and hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To test this hypothesis, we studied CypD acetylation in patients with essential hypertension, defined a pathogenic role of CypD acetylation in deacetylation mimetic CypD-K166R mutant mice and endothelial-specific GCN5L1 (general control of amino acid synthesis 5 like 1)-deficient mice using an Ang II (angiotensin II) model of hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Arterioles from hypertensive patients had 280% higher CypD acetylation coupled with reduced Sirt3 (sirtuin 3) and increased GCN5L1 levels. GCN5L1 regulates mitochondrial protein acetylation and promotes CypD acetylation, which is counteracted by mitochondrial deacetylase Sirt3. In human aortic endothelial cells, GCN5L1 depletion prevents superoxide overproduction. Deacetylation mimetic CypD-K166R mice were protected from vascular oxidative stress, endothelial dysfunction, and Ang II-induced hypertension. Ang II-induced hypertension increased mitochondrial GCN5L1 and reduced Sirt3 levels resulting in a 250% increase in GCN5L1/Sirt3 ratio promoting CypD acetylation. Treatment with mitochondria-targeted scavenger of cytotoxic isolevuglandins normalized GCN5L1/Sirt3 ratio, reduced CypD acetylation, and attenuated hypertension. The role of mitochondrial acetyltransferase GCN5L1 in the endothelial function was tested in endothelial-specific GCN5L1 knockout mice. Depletion of endothelial GCN5L1 prevented Ang II-induced mitochondrial oxidative stress, reduced the maladaptive switch of vascular metabolism to glycolysis, prevented inactivation of endothelial nitric oxide, preserved endothelial-dependent relaxation, and attenuated hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These data support the pathogenic role of CypD acetylation in endothelial dysfunction and hypertension. We suggest that targeting cytotoxic mitochondrial isolevuglandins and GCN5L1 reduces CypD acetylation, which may be beneficial in cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38639088/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38639088</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323596>10.1161/CIRCRESAHA.123.323596</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38639088</guid>
<pubDate>Fri, 19 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Anna Dikalova</dc:creator>
<dc:creator>Daniel Fehrenbach</dc:creator>
<dc:creator>Vladimir Mayorov</dc:creator>
<dc:creator>Alexander Panov</dc:creator>
<dc:creator>Mingfang Ao</dc:creator>
<dc:creator>Louise Lantier</dc:creator>
<dc:creator>Venkataraman Amarnath</dc:creator>
<dc:creator>Marcos G Lopez</dc:creator>
<dc:creator>Frederic T Billings Iv</dc:creator>
<dc:creator>Michael N Sack</dc:creator>
<dc:creator>Sergey Dikalov</dc:creator>
<dc:date>2024-04-19</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Mitochondrial CypD Acetylation Promotes Endothelial Dysfunction and Hypertension</dc:title>
<dc:identifier>pmid:38639088</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323596</dc:identifier>
</item>
<item>
<title>Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38634276/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>Cardiac sarcoidosis is an infiltrative cardiomyopathy that results from granulomatous inflammation of the myocardium and may present with high-grade conduction disease, ventricular arrhythmias, and right or left ventricular dysfunction. Over the past several decades, the prevalence of cardiac sarcoidosis has increased. Definitive histological confirmation is often not possible, so clinicians frequently face uncertainty about the accuracy of diagnosis. Hence, the likelihood of cardiac sarcoidosis...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 18. doi: 10.1161/CIR.0000000000001240. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiac sarcoidosis is an infiltrative cardiomyopathy that results from granulomatous inflammation of the myocardium and may present with high-grade conduction disease, ventricular arrhythmias, and right or left ventricular dysfunction. Over the past several decades, the prevalence of cardiac sarcoidosis has increased. Definitive histological confirmation is often not possible, so clinicians frequently face uncertainty about the accuracy of diagnosis. Hence, the likelihood of cardiac sarcoidosis should be thought of as a continuum (definite, highly probable, probable, possible, low probability, unlikely) rather than in a binary fashion. Treatment should be initiated in individuals with clinical manifestations and active inflammation in a tiered approach, with corticosteroids as first-line treatment. The lack of randomized clinical trials in cardiac sarcoidosis has led to treatment decisions based on cohort studies and consensus opinions, with substantial variation observed across centers. This scientific statement is intended to guide clinical practice and to facilitate management conformity by providing a framework for the diagnosis and management of cardiac sarcoidosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38634276/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38634276</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001240>10.1161/CIR.0000000000001240</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38634276</guid>
<pubDate>Thu, 18 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Richard K Cheng</dc:creator>
<dc:creator>Michelle M Kittleson</dc:creator>
<dc:creator>Craig J Beavers</dc:creator>
<dc:creator>David H Birnie</dc:creator>
<dc:creator>Ron Blankstein</dc:creator>
<dc:creator>Paco E Bravo</dc:creator>
<dc:creator>Nisha A Gilotra</dc:creator>
<dc:creator>Marc A Judson</dc:creator>
<dc:creator>Kristen K Patton</dc:creator>
<dc:creator>Leonie Rose-Bovino</dc:creator>
<dc:creator>American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2024-04-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38634276</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001240</dc:identifier>
</item>
<item>
<title>A Leadership Program to Support Career Development of Cardiovascular Chief Fellows</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631779/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 23;83(16):1623-1625. doi: 10.1016/j.jacc.2024.02.030.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631779/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38631779</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.030>10.1016/j.jacc.2024.02.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631779</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Emily K Zern</dc:creator>
<dc:creator>Tripti Gupta</dc:creator>
<dc:creator>Hyeon-Ju Ryoo Ali</dc:creator>
<dc:creator>Prashanth Thakker</dc:creator>
<dc:creator>Nosheen Reza</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Leadership Program to Support Career Development of Cardiovascular Chief Fellows</dc:title>
<dc:identifier>pmid:38631779</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.030</dc:identifier>
</item>
<item>
<title>RESPONSE: Dispatches From a Neighboring Land</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 23;83(16):1622. doi: 10.1016/j.jacc.2024.01.038. Epub 2024 Mar 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38631778</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.038>10.1016/j.jacc.2024.01.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631778</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Karen P Alexander</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>RESPONSE: Dispatches From a Neighboring Land</dc:title>
<dc:identifier>pmid:38631778</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.038</dc:identifier>
</item>
<item>
<title>Reflections on the Practice of Geriatric Cardiology After a Mid-Career Geriatrics Fellowship</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 23;83(16):1619-1622. doi: 10.1016/j.jacc.2024.01.035.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38631777</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.035>10.1016/j.jacc.2024.01.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631777</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Ashok Krishnaswami</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reflections on the Practice of Geriatric Cardiology After a Mid-Career Geriatrics Fellowship</dc:title>
<dc:identifier>pmid:38631777</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.035</dc:identifier>
</item>
<item>
<title>Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631776/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to reduce adverse cardiovascular events in patients with type 2 diabetes mellitus, all-cause mortality, and heart failure hospitalization in patients with heart failure, as well as adverse renal outcomes. However, concerns regarding the heightened risk of genitourinary (GU) infections, particularly urinary tract infections, remain a significant barrier to their wider adoption. Addressing these misconceptions using existing...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 23;83(16):1568-1578. doi: 10.1016/j.jacc.2024.01.040.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to reduce adverse cardiovascular events in patients with type 2 diabetes mellitus, all-cause mortality, and heart failure hospitalization in patients with heart failure, as well as adverse renal outcomes. However, concerns regarding the heightened risk of genitourinary (GU) infections, particularly urinary tract infections, remain a significant barrier to their wider adoption. Addressing these misconceptions using existing evidence is needed to ensure proper risk-benefit assessment and optimal utilization of this efficacious therapy. This review aims to provide a balanced perspective on the evidence-based cardiovascular and renal benefits of SGLT2is and the associated risk of GU infections. We also summarize and propose clinical practice considerations for SGLT2i-associated GU infections focusing on patients with cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631776/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38631776</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.040>10.1016/j.jacc.2024.01.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631776</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Veraprapas Kittipibul</dc:creator>
<dc:creator>Zachary L Cox</dc:creator>
<dc:creator>Supavit Chesdachai</dc:creator>
<dc:creator>Mona Fiuzat</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:38631776</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.040</dc:identifier>
</item>
<item>
<title>Measurement and Application of Incidentally Detected Coronary Calcium: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38631775/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240423203844&amp;v=2.18.0.post9+e462414
      <description>Coronary artery calcium (CAC) scoring is a powerful tool for atherosclerotic cardiovascular disease risk stratification. The nongated, noncontrast chest computed tomography scan (NCCT) has emerged as a source of CAC characterization with tremendous potential due to the high volume of NCCT scans. Application of incidental CAC characterization from NCCT has raised questions around score accuracy, standardization of methodology including the possibility of deep learning to automate the process, and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 23;83(16):1557-1567. doi: 10.1016/j.jacc.2024.01.039.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Coronary artery calcium (CAC) scoring is a powerful tool for atherosclerotic cardiovascular disease risk stratification. The nongated, noncontrast chest computed tomography scan (NCCT) has emerged as a source of CAC characterization with tremendous potential due to the high volume of NCCT scans. Application of incidental CAC characterization from NCCT has raised questions around score accuracy, standardization of methodology including the possibility of deep learning to automate the process, and the risk stratification potential of an NCCT-derived score. In this review, the authors aim to summarize the role of NCCT-derived CAC in preventive cardiovascular health today as well as explore future avenues for eventual clinical applicability in specific patient populations and broader health systems.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38631775/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240423203844&v=2.18.0.post9+e462414">38631775</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.039>10.1016/j.jacc.2024.01.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38631775</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Shyon Parsa</dc:creator>
<dc:creator>Adam Saleh</dc:creator>
<dc:creator>Viraj Raygor</dc:creator>
<dc:creator>Natalie Hoeting</dc:creator>
<dc:creator>Anjali Rao</dc:creator>
<dc:creator>Ann Marie Navar</dc:creator>
<dc:creator>Anand Rohatgi</dc:creator>
<dc:creator>Fernando Kay</dc:creator>
<dc:creator>Suhny Abbara</dc:creator>
<dc:creator>Amit Khera</dc:creator>
<dc:creator>Parag H Joshi</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Measurement and Application of Incidentally Detected Coronary Calcium: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:38631775</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.039</dc:identifier>
</item>





























</channel>
</rss>